Clinical Trial

Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

Study acronym: MAK
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of immunotherapy in the first-line treatment of metastatic melanoma in Slovenia and to investigate the association between PD-L1 expression and treatment response. The study aims to determine the relationship between exosomal PD-L1 miRNA expression, PD-L1 expression in tumor tissue, and PD-L1 expression on the surface of immune cells, and response to immunotherapy. The study will also evaluate the association between immune-related adverse events and survival.
Trial Details
NCT Number NCT07422779
Lead Sponsor Institute of Oncology Ljubljana
Conditions Metastatic Melanoma, Skin Cancer
Enrollment 100 participants
Start Date 2022-03-01
Primary Completion 2027-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-20